Alamar Biosciences, Inc.

🌍 Expanding Global Access to Precision Proteomics! Alamar Biosciences is partnering with five leading distributors to bring our high-sensitivity proteomics solutions to more researchers worldwide! 🎉 🔹 GeneWorks – Australia & New Zealand 🔹 Genomax – Singapore 🔹 PhileKorea – South Korea 🔹 Scrum Inc. – Japan 🔹 Spinco – India “These partners will help accelerate access to our next-gen proteomics tools for biomarker discovery, drug development, and disease research,” said Yuling Luo, Ph.D., CEO of Alamar Biosciences. 📢 Learn more: https://ow.ly/ATOO50VkGlX #Proteomics #LifeSciences #Biomarkers #DrugDiscovery #ScientificInnovation

We're thrilled to be attending the 13th Annual Parkinson’s & Drug Development Summit in Boston today! Join our partnership presentation this morning to hear from Dr. Christopher Bunker, VP of Biopharma Business Development at Alamar, on how #NULISA, the only high-plex, high-sensitivity platform, is transforming biomarker research for neurodegenerative diseases and treatment response. We look forward to connecting with experts driving innovation in Parkinson’s research and neurodegenerative disease drug development 👉 https://ow.ly/iXTv50VktPF #ParkinsonsDisease #Neurodegeneration #Biomarkers #DrugDevelopment

Don’t Miss Our Technology Showcase at #ABRF2025! Join us on Monday, March 24 at 7:45 am in Skyyview 4 to hear Dr. Robert Chen from Weill Cornell Medicine, highlight how our #NULISAseq Panels for human and mouse are advancing #proteomics research with high sensitivity, unlocking new insights in multi-omic studies. Be sure to stop by booth 233 to connect with our team and discover how our cutting-edge #NULISA technology can elevate your research 👉 https://ow.ly/zjMg50VkcXo

🚨 We're heading to Las Vegas for #ABRF2025! 🚨 As a returning sponsor, we are excited to connect with the core facility and research community at this premier event. Stop by booth 233 to learn how our cutting-edge #NULISA technology supports breakthroughs in #immunology, #neurodegeneration, and cancer research—empowering biomolecular resource facilities with advanced solutions for multi-omics and precision medicine. Meet our team and discover how we can support your research goals! Learn more about our ABRF activities here 👉 https://ow.ly/Q5RT50Vhyi3 #CoreFacilities #PrecisionMedicine #CancerResearch

🧠 Thank you for joining us at Translation 2025! 🧠 As the event comes to a close, we’re grateful for the insightful discussions and collaborations driving progress in dementia research. At Alamar Biosciences, we are dedicated to advancing research for early disease detection for neurologic disorders like #dementia and Alzheimer's disease with our groundbreaking #NULISA protein #biomarker detection technology. Learn more about NULISA and its impact on neurodegenerative disease research 👉 https://ow.ly/3lNU50VioUK #Translation2025 #DementiaResearch #DPUK #DementiasPlatformUK

🚨 We're heading to Las Vegas for #ABRF2025! 🚨 As a returning sponsor, we are excited to connect with the core facility and research community at this premier event. Stop by booth 233 to learn how our cutting-edge #NULISA technology supports breakthroughs in #immunology, #neurodegeneration, and cancer research—empowering biomolecular resource facilities with advanced solutions for multi-omics and precision medicine. Meet our team and discover how we can support your research goals! Learn more about our ABRF activities here 👉 https://ow.ly/Q5RT50Vhyi3 #CoreFacilities #PrecisionMedicine #CancerResearch

Join us at #WIRM2025! Don’t miss our Lunch Symposium on Friday, at 12:25 pm, where Dr. Huseyn Babayev (Swiss Institute of Allergy and Asthma Research) and Dr. James Eastall (University of Nottingham) will share how #NULISA unlocks ultra-sensitive proteomics to reveal dynamic changes in plasma biomarkers—from air pollution exposure to the effects of Mepolizumab on inflammation in asthma. Be sure to visit us at Booth 113 network and learn about our cutting-edge solutions. See you there! 👋 https://ow.ly/qQHx50Vgbzr #Proteomics #ImmuneRegulation

We're thrilled to exhibit at the 19th World Immune Regulation Meeting in Davos this week! 🧬✨ Don't miss our Lunch Symposium on March 14, where we’ll dive into how #NULISA™ is revolutionizing early disease detection and enabling precision medicine. Stop by booth 113 for the opportunity to network and learn about our cutting-edge solutions. See you in there! https://ow.ly/coqb50VfnA2 #WIRM2025 #ImmuneRegulation #Proteomics

We’re thrilled to welcome Banner Health to Alamar Biosciences’ Certified Service Provider (CSP) Program! 🎉 As a leader in neurodegenerative disease research, Banner Health is leveraging our #NULISA technology to advance biomarker detection for Alzheimer’s disease. By applying high-sensitivity biomarker detection to clinical samples, they are advancing community-based screening for earlier Alzheimer’s detection and better patient outcomes. Stay tuned as we continue to expand our CSP network, making advanced proteomics more accessible than ever. 🔗 Learn more about our CSP Program: https://ow.ly/T68z50V2vLn #BiomarkerDetection #AlzheimersDisease #PrecisionMedicine #Neuroscience #Proteomics

🚨 New Poster Alert! 🚨 We're excited to share our latest findings on Proteome Profiling of Dried Blood Spots (DBS) and Dried Plasma Spots (DPS) using the #NULISAseq Inflammation and CNS Disease Panels. 🔬 Key Findings: ✅ High detectability of biomarkers like NFL, GFAP, and pTaus in DBS and DPS. ✅ Over 85% detection success across our Inflammation and CNS Disease panels. ✅ Strong correlation with matched whole blood and plasma samples. Learn more and explore the full poster details 👉 https://ow.ly/pmEU50V7omM